克里斯特尔生物科技公司（Krystal Biotech Inc，股票代码：KRYS）今日盘中大跌15.20%，主要原因是公司公布的季度业绩未达市场预期。
根据公司最新发布的财务报告，截至3月31日的季度调整后每股收益为1.20美元，虽然大幅高于去年同期的0.03美元，但低于分析师平均预期的1.37美元。公司营收同比增长94.9%，达到8818万美元，但仍未达到分析师预期的9624万美元。这一业绩表现可能是引发投资者信心下降的主要原因。
值得注意的是，近期分析师对该公司的盈利预测出现了负面调整。过去30天内，有四位分析师下调了对公司的盈利预期。尽管如此，华尔街分析师对该公司的总体评级仍维持在"买入"水平，12个月目标价中位数为215.00美元。这表明尽管短期内公司表现不佳，但长期前景仍被看好。然而，当前的股价大跌反映了市场对公司近期业绩的失望情绪。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.